A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2011-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2125.2011.04015.xPMID 21575034PMCID PMC3175510
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

  2010cited by this paper
• Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models

  2010cited by this paper
• Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

  2009cited by this paper
• Approximations of the target-mediated drug disposition model and identifiability of model parameters

  2008influential reference
• Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters

  2008cited by this paper
• Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer.

  2008cited by this paper
• Clinical pharmacokinetics of bevacizumab in patients with solid tumors

  2008cited by this paper
• Vascular endothelial growth factor (VEGF) inhibition--a critical review.

  2007cited by this paper
• Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

  2007influential reference
• A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

  2007cited by this paper
• Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model

  2006cited by this paper
• Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide

  2006cited by this paper
• A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis

  2006cited by this paper
• Target-mediated drug disposition and dynamics.

  2006cited by this paper
• Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2005cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

  2002influential reference
• VEGF-Trap: A VEGF blocker with potent antitumor effects

  2002cited by this paper
• General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2001cited by this paper
• A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.

  2001cited by this paper
• Serum vascular endothelial growth factor is often elevated in disseminated cancer.

  1997cited by this paper
• ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS

  1971cited by this paper

• Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration

  2024influential citation
• EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2024influential citation
• Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study

  2024cites this paper
• Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration

  2023cites this paper
• A novel LC-MS/MS approach to the pharmacokinetic study of free and bound aflibercept simultaneously

  2020cites this paper
• Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs

  2017cites this paper
• Aflibercept for diabetic macular edema: a concise review

  2017cites this paper
• Preclinical PET Study of Intravitreal Injections.

  2017cites this paper
• A Tutorial on Target-Mediated Drug Disposition (TMDD) Models

  2015cites this paper
• Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

  2015cites this paper
• Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development—Opportunities and challenges

  2015cites this paper
• Integrated Quantitation of Biotherapeutic Drug–Target Binding, Biomarkers, and Clinical Response to Support Rational Dose Regimen Selection

  2015cites this paper
• Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer.

  2014cites this paper
• Estimating the uncertainty of parameters in non-linear mixed-effects models by bootstrap : simulation studies to compare different bootstrap methods

  2014cites this paper
• Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedside

  2014cites this paper
• Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia

  2013cites this paper
• Mechanistic Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in Deciphering Interplay Between a Monoclonal Antibody and Its Soluble Target in Cynomolgus Monkeys

  2013cites this paper
• What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

  2013cites this paper
• Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema.

  2013cites this paper
• Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors

  2013cites this paper
• Développement de modèles mécanistiques et évaluation de l'incertitude des paramètres par bootstrap : application aux médicaments anti-angiogéniques

  2013cites this paper
• Aflibercept for the treatment of neovascular age-related macular degeneration.

  2012cites this paper
• Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases

  2012cites this paper